HONG KONG – With a series of advancements in the area of biosimilar development, China’s Shanghai Fosun Pharmaceutical Group Co. Ltd. is getting closer to becoming the first domestic company to market a biosimilar product in China.

As part of a push to strengthen the supply of pharmaceuticals in the country, Nigeria is working to eliminate open markets in favor of a Pharmaceutical Coordinated Wholesale Center.